Study S001883

The Role of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment of Overweight/Obese Individuals for Improving Adverse Cardiometabolic Phenotype Associated With CAV-1 Deficiency

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06069622
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 30
Start: 2023-11-01
Primary completion: 2026-10-01
Lead sponsor: Brigham and Women's Hospital
Conditions: Overweight and Obesity
Interventions: DIAGNOSTIC_TEST:24-hour ambulatory blood pressure; DIETARY_SUPPLEMENT:Liberal salt diet
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Blood pressure response to GLP-1 RA treatment [20 weeks]
Weight loss response to GLP-1 RA treatment [20 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.